Clinical trials: Burkitt Lymphoma
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive
Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Background: Burkitt lymphoma/leukemia (BL) is highly treatable, but most of the standard therapies require multiple doses of intensive chemotherapy that may require long hospital stays and frequently have severe side effects.
- Conditions
- Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
- Trial name
- NCT01092182
- Testing
- EPOCH-R, EPOCH-RR
- Where
- 30 sites in United States
- Volunteers
- 194 people
- Sponsor
- National Cancer Institute (NCI)
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes
The purpose of this study is to evaluate the safety, efficacy and blood kinetics of autologous T cells genetically modified to express anti-CD19 Chimeric Antigen Receptor in patients with relapsed or refractory B-Cell Non-Hodgkin…
- Trial name
- NCT02134262
- Testing
- Cyclophosphamide or Bendamustine, Dose Level -1, Dose Level 1
- Where
- Japan
- Volunteers
- 18 people
- Sponsor
- Jichi Medical University
Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia
Low-Intensity Chemotherapy and Venetoclax in Treating Patients With Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia
This phase I/II trial studies the side effects and best dose of venetoclax and how well it works in combination with low-intensity chemotherapy in patients with B- or T-cell acute lymphoblastic leukemia that has not responded to…
- Conditions
- Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia
- Trial name
- NCT03808610
- Testing
- Cyclophosphamide, Cytarabine, Dexamethasone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
B-Cell Leukemia, Non-Hodgkin's Lymphoma
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
This is a phase I dose-finding trial of an autologous CD22 targeting chimeric antigen receptor (CAR)-T cell product, called CLIC-2201, for participants with relapsed/refractory B cell malignancies.
- Conditions
- B-Cell Leukemia, Non-Hodgkin's Lymphoma, B-cell Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma
- Trial name
- NCT06208735
- Testing
- CLIC-2201
- Where
- 7 sites in Canada
- Volunteers
- 24 people
- Sponsor
- British Columbia Cancer Agency
Non-Hodgkins Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Aurora kinase inhibitor AT9283 (AT9283) may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00443976
- Testing
- Aurora kinase inhibitor AT9283
- Where
- 2 sites in Canada
- Volunteers
- 35 people
- Sponsor
- NCIC Clinical Trials Group
B-cell Acute Lymphoblastic Leukemia
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
- Trial name
- NCT06559189
- Testing
- CD19x22 CAR T
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of Colorado, Denver
Lymphoma
Combination Chemotherapy With or Without Amifostine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Hodgkin's Disease Undergoing Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Trial name
- NCT00003143
- Testing
- Amifostine, DHAP
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs in chemotherapy, such as ifosfamide, carboplatin, and etoposide, work in different ways to stop the growth of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00788125
- Testing
- carboplatin, dasatinib, etoposide phosphate
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- City of Hope Medical Center
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia
RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells.
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00612716
- Testing
- busulfan, cyclophosphamide, Stem cell infusion
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Stem Cell Transplantation in Treating Patients With Hematologic Cancer
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy and radiation therapy used to kill tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT00004904
- Testing
- anti-thymocyte globulin, filgrastim, cladribine
- Where
- United States
- Sponsor
- Northwestern University
Brain Tumor, Central Nervous System Tumors
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and…
- Conditions
- Brain Tumor, Central Nervous System Tumors, Cachexia, Leukemia
- Trial name
- NCT00066248
- Testing
- cyproheptadine hydrochloride, megestrol acetate
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 70 people
- Sponsor
- University of South Florida
B-cell Acute Lymphoblastic Leukemia, B-ALL
Anti-CD19 Universal CAR-T Cells for r/r CD19+ B-ALL
This is a single-arm, single-center, open-labeled clinical study to evaluate the safety and efficacy of LstCAR019 injection for patients with relapsed/refractory(r/r) B-cell Acute Lymphoblastic Leukemia(B-ALL).
- Trial name
- NCT05571540
- Testing
- U-CAR-T Cells (LstCAR019)
- Where
- China
- Sponsor
- Kunming Hope of Health Hospital
Leukemia, Lymphoma
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating patients who have…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00003885
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Our Lady of Mercy Medical Center
B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Monoclonal antibodies, such as yttrium Y 90 ibritumomab tiuxetan, can block find cancer cells and either kill them or carry cancer-killing substances to them without harming normal cells.
- Conditions
- B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00119392
- Testing
- rituximab, cyclosporine, fludarabine phosphate
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Genetic Susceptibility and Risk of Second Cancers in Patients Who Have Undergone Stem Cell Transplant for Cancer
RATIONALE: Identifying genes that increase a person's susceptibility to second cancers may help the study of cancer treatment. PURPOSE: This study is looking at genetic susceptibility and risk of second cancers in patients who…
- Trial name
- NCT00949052
- Testing
- DNA analysis, polymorphism analysis, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
B-Cell Acute Lymphoblastic Leukemia, Adult
Sequential CD19 and CD22 CAR-T Therapy for Newly Diagnosed Ph- B-ALL
Clinical Trial for the Safety and Efficacy of Sequential CD19 and CD22 CAR-T Therapy for Adult Patients With Newly Diagnosed Ph Chromosome Negative B-cell Acute Lymphoblastic Leukemia
- Trial name
- NCT04740203
- Testing
- CAR-T cells targeting CD19 and CD22
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase II trial to study the effectiveness of oxaliplatin in treating patients who have relapsed or refractory non-Hodgkin's lymphoma.
- Conditions
- Angioimmunoblastic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma
- Trial name
- NCT00006473
- Testing
- oxaliplatin
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- National Cancer Institute (NCI)
Lymphoma, Small Intestine Cancer
PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of PS-341 in treating patients who have advanced solid…
- Conditions
- Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00004002
- Testing
- bortezomib
- Where
- 5 sites in United States
- Sponsor
- NYU Langone Health
Chronic Myeloproliferative Disorders, Fatigue
St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer
RATIONALE: Giving St. John's wort may be effective in relieving fatigue in patients with cancer who are undergoing chemotherapy or hormone therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of St.
- Conditions
- Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma
- Trial name
- NCT00005805
- Testing
- St. John's wort
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
B Cell Lymphoma, B-cell Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
The primary objective of this study is to evaluate the safety and clinical activity of anti-CD19 Chimeric Antigen Receptor T cells (KD-019 CAR-T)infusion in the treatment of relapsed/refractory B-cell Lymphoma and B-cell acute…
- Trial name
- NCT03854994
- Testing
- Anti-CD19 CAR-T Cells Injection
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Yan'an Affiliated Hospital of Kunming Medical University